Constraints on the Availability of Human Hepatocytes
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: 2026-06-29.
No other company in this theme has enough history to compare yet.
- FY2025MitigatedAnnual report
「The company purchases human hepatocytes from a single donor in large quantities and stores them frozen for use in PXB mouse production, enabling it to continue production.」
For human hepatocytes that depend on overseas sourcing, the company states that purchasing large quantities of cells from a single donor and storing them frozen enables continued production. - FY2023RestatedAnnual report
「Human hepatocytes used for transplantation cannot be obtained domestically and are imported from overseas suppliers through distributors. If obtaining human hepatocytes becomes difficult in the future because of higher purchase prices, regulatory restrictions or other factors, production of PXB mice may be constrained, potentially affecting the Group's business development and performance.」
The company continues to identify price, regulatory and supply-constraint risks for human hepatocytes that depend on overseas imports. - FY2018RestatedAnnual report
「Human hepatocytes used for transplantation cannot be obtained domestically and are imported from overseas suppliers through distributors. If obtaining human hepatocytes becomes difficult in the future because of higher purchase prices, regulatory restrictions or other factors, production of PXB mice may be constrained, potentially affecting the Group's business development and performance.」
The company reaffirms the risks relating to price, regulatory restrictions and supply constraints associated with importing human hepatocytes from overseas suppliers. - FY2017RestatedAnnual report
「Human hepatocytes used for transplantation cannot be obtained domestically and are imported from overseas suppliers through distributors. If obtaining human hepatocytes becomes difficult in the future because of higher purchase prices, regulatory restrictions or other factors, production of PXB mice may be constrained, potentially affecting the Group's business development and performance.」
The company reiterates the risk of supply constraints for human hepatocytes obtained from overseas. - FY2016First statedAnnual report
「Human hepatocytes used for transplantation cannot be obtained domestically and are imported from overseas suppliers through distributors. If obtaining human hepatocytes becomes difficult in the future because of higher purchase prices, regulatory restrictions or other factors, production of PXB mice may be constrained, potentially affecting the Group's business development and performance.」
The company identifies supply constraints caused by higher prices and regulatory restrictions as risks for human hepatocytes that depend on overseas imports.